{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:29:39Z","timestamp":1793651379636,"version":"4.5.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41375-026-02958-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:35:14Z","timestamp":1776771314000},"page":"1261-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2816-3011","authenticated-orcid":false,"given":"Arno H.","family":"Houtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Arfeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Strullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-6089","authenticated-orcid":false,"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-1511","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Cav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-3037","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Caye-Eude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.","journal-title":"JAMA Oncol"},{"key":"2958_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","volume":"129","author":"D Campana","year":"2017","unstructured":"Campana D, Pui CH. Minimal residual disease\u2013guided therapy in childhood acute lymphoblastic leukemia. Blood. 2017;129:1913\u20138.","journal-title":"Blood"},{"key":"2958_CR3","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1200\/JCO.23.01286","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol. 2023;41:5579\u201391.","journal-title":"J Clin Oncol"},{"key":"2958_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14737159.2017.1377073","volume":"17","author":"V Nunes","year":"2017","unstructured":"Nunes V, Cazzaniga G, Biondi A. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn. 2017;17:953\u201363.","journal-title":"Expert Rev Mol Diagn"},{"key":"2958_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VHJ van der Velden","year":"2007","unstructured":"van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"2958_CR6","unstructured":"Heyman M ALLTogether1 \u2013 A treatment study protocol of the ALLTogether Consortium for children and young adults (0\u201345 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). Karolinska University Hospital; 2020. Report No.: NCT04307576."},{"key":"2958_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, Panzer-Gr\u00fcmayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771\u201382.","journal-title":"Leukemia"},{"key":"2958_CR8","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/leu.2012.246","volume":"26","author":"AW Langerak","year":"2012","unstructured":"Langerak AW, Groenen PJTA, Br\u00fcggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159\u201371.","journal-title":"Leukemia"},{"key":"2958_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Br\u00fcggemann","year":"2010","unstructured":"Br\u00fcggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008. Leukemia. 2010;24:521\u201335.","journal-title":"Leukemia"},{"key":"2958_CR10","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/s41375-020-0774-4","volume":"34","author":"Z Li","year":"2020","unstructured":"Li Z, Jiang N, Lim EH, Chin WHN, Lu Y, Chiew KH, et al. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq. Leukemia. 2020;34:2418\u201329.","journal-title":"Leukemia"},{"key":"2958_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VHJ van der Velden","year":"2003","unstructured":"van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013\u201334.","journal-title":"Leukemia"},{"key":"2958_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/beha.2002.0184","volume":"15","author":"T Szczepa\u0144ski","year":"2002","unstructured":"Szczepa\u0144ski T, Flohr T, van der Velden VHJ, Bartram CR, van Dongen JJM. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pr Res Clin Haematol. 2002;15:37\u201357.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1038\/sj.leu.2403081","volume":"17","author":"T Szczepa\u0144ski","year":"2003","unstructured":"Szczepa\u0144ski T, Velden VHJ, van der, Raff T, Jacobs DCH, Wering ER, et al. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL. Leukemia. 2003;17:2149\u201356.","journal-title":"Leukemia"},{"key":"2958_CR14","first-page":"737","volume":"88","author":"A Guggemos","year":"2003","unstructured":"Guggemos A, Eckert C, Szczepanski T, Hanel C, Taube T, van der Velden VHJ, et al. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia. Haematologica. 2003;88:737\u201346.","journal-title":"Haematologica"},{"key":"2958_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/leu.2011.89","volume":"25","author":"C Eckert","year":"2011","unstructured":"Eckert C, Flohr T, Koehler R, Hagedorn N, Moericke A, Stanulla M, et al. Very early\/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia. 2011;25:1305\u201313.","journal-title":"Leukemia"},{"key":"2958_CR16","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1182\/blood-2003-05-1455","volume":"102","author":"A Li","year":"2003","unstructured":"Li A, Zhou J, Zuckerman D, Rue M, Dalton V, Lyons C, et al. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood. 2003;102:4520\u20136.","journal-title":"Blood"},{"key":"2958_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/bmt.2008.122","volume":"42","author":"E Fronkova","year":"2008","unstructured":"Fronkova E, Muzikova K, Mejstrikova E, Kovac M, Formankova R, Sedlacek P, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transpl. 2008;42:187\u201396.","journal-title":"Bone Marrow Transpl"},{"key":"2958_CR18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"2958_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","volume":"482","author":"AS Duffield","year":"2023","unstructured":"Duffield AS, Mullighan CG, Borowitz MJ. International consensus classification of acute lymphoblastic leukemia\/lymphoma. Virchows Arch Int J Pathol. 2023;482:11\u201326.","journal-title":"Virchows Arch Int J Pathol"},{"key":"2958_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s43018-025-00987-2","volume":"6","author":"I Iacobucci","year":"2025","unstructured":"Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, et al. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat Cancer. 2025;6:1242\u201362.","journal-title":"Nat Cancer"},{"key":"2958_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjh.17879","volume":"197","author":"DTO Yeung","year":"2022","unstructured":"Yeung DTO, Osborn MP, White DL. B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. Br J Haematol. 2022;197:13\u201327.","journal-title":"Br J Haematol"},{"key":"2958_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"2958_CR23","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/leu.2010.174","volume":"24","author":"J Score","year":"2010","unstructured":"Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Sim\u00f5es MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR\u2013ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742\u201350.","journal-title":"Leukemia"},{"key":"2958_CR24","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.leukres.2008.11.001","volume":"33","author":"H von Goessel","year":"2009","unstructured":"von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T, et al. Cluster analysis of genomic ETV6\u2013RUNX1 (TEL\u2013AML1) fusion sites in childhood acute lymphoblastic leukemia. Leuk Res. 2009;33:1082\u20138.","journal-title":"Leuk Res"},{"key":"2958_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02053-4","volume":"23","author":"L Hovorkova","year":"2024","unstructured":"Hovorkova L, Winkowska L, Skorepova J, Krumbholz M, Benesova A, Polivkova V, et al. Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients. Mol Cancer. 2024;23:138.","journal-title":"Mol Cancer"},{"key":"2958_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1073\/pnas.0406994102","volume":"102","author":"C Meyer","year":"2005","unstructured":"Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA. 2005;102:449\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2958_CR27","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJM van Dongen","year":"2003","unstructured":"van Dongen JJM, Langerak AW, Br\u00fcggemann M, Evans PaS, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257\u2013317.","journal-title":"Leukemia"},{"key":"2958_CR28","doi-asserted-by":"publisher","first-page":"e0166126","DOI":"10.1371\/journal.pone.0166126","volume":"11","author":"M Duez","year":"2016","unstructured":"Duez M, Giraud M, Herbert R, Rocher T, Salson M, Thonier F. Vidjil: A Web Platform for Analysis of High-Throughput Repertoire Sequencing. PLOS ONE. 2016;11:e0166126.","journal-title":"PLOS ONE"},{"key":"2958_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-409","volume":"15","author":"M Giraud","year":"2014","unstructured":"Giraud M, Salson M, Duez M, Villenet C, Quief S, Caillault A, et al. Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics. 2014;15:409.","journal-title":"BMC Genomics"},{"key":"2958_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet Lond Engl. 1986;1:307\u201310.","journal-title":"Lancet Lond Engl"},{"key":"2958_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/s41375-025-02565-y","volume":"39","author":"J Geyer","year":"2025","unstructured":"Geyer J, Opoku KB, Lin J, Ramkissoon L, Mullighan C, Bhakta N, et al. Real-time genomic characterization of pediatric acute leukemia using adaptive sampling. Leukemia. 2025;39:1069\u201377.","journal-title":"Leukemia"},{"key":"2958_CR32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.20.02333","volume":"39","author":"J Stutterheim","year":"2021","unstructured":"Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the interfant-06 protocol. J Clin Oncol. 2021;39:652\u201362.","journal-title":"J Clin Oncol"},{"key":"2958_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","volume":"38","author":"VHJ van der Velden","year":"2024","unstructured":"van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, et al. Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia. 2024;38:1315\u201322.","journal-title":"Leukemia"},{"key":"2958_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70124","volume":"9","author":"K Seferna","year":"2025","unstructured":"Seferna K, Svaton M, Rennerova A, Skotnicova A, Reznickova L, Valova T, et al. NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk. HemaSphere. 2025;9:e70124.","journal-title":"HemaSphere"},{"key":"2958_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood.2022017003","volume":"141","author":"M Svaton","year":"2023","unstructured":"Svaton M, Skotnicova A, Reznickova L, Rennerova A, Valova T, Kotrova M, et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood. 2023;141:529\u201333.","journal-title":"Blood"},{"key":"2958_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","volume":"19","author":"A Monter","year":"2019","unstructured":"Monter A, Nomded\u00e9u JF. ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diagn. 2019;19:571\u20138.","journal-title":"Expert Rev Mol Diagn"},{"key":"2958_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exphem.2021.03.005","volume":"98","author":"MH Hansen","year":"2021","unstructured":"Hansen MH, C\u00e9dile O, Larsen TS, Abildgaard N, Nyvold CG. Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements\u2014how low can you go? Exp Hematol. 2021;98:14\u201324.","journal-title":"Exp Hematol"},{"key":"2958_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"G Cazzaniga","year":"2018","unstructured":"Cazzaniga G, Lorenzo PD, Alten J, R\u00f6ttgers S, Hancock J, Saha V, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T-cell receptor and BCR\/ABL1 methodologies. Haematologica. 2018;103:107\u201315.","journal-title":"Haematologica"},{"key":"2958_CR39","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","volume":"36","author":"J Zuna","year":"2022","unstructured":"Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022;36:2793\u2013801.","journal-title":"Leukemia"},{"key":"2958_CR40","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood.2023021501","volume":"142","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood. 2023;142:1806\u201317.","journal-title":"Blood"},{"key":"2958_CR41","doi-asserted-by":"publisher","first-page":"E269","DOI":"10.1002\/ajh.27022","volume":"98","author":"J Zuna","year":"2023","unstructured":"Zuna J, Hovorkova L, Krotka J, Winkowska L, Novak Z, Sramkova L, et al. Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track? Am J Hematol. 2023;98:E269\u201371.","journal-title":"Am J Hematol"},{"key":"2958_CR42","doi-asserted-by":"publisher","unstructured":"Outersterp I, Van Boer JM, Sonneveld E, Jong AX, Ve Nierkens S, et al. Multilineage involvement in ABL-class fusion\u2013positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.287931.","DOI":"10.3324\/haematol.2025.287931"},{"key":"2958_CR43","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1097\/HS9.0000000000000967","volume":"7","author":"I van Outersterp","year":"2023","unstructured":"van Outersterp I, van der Velden VHJ, Hoogeveen PG, Vaitkevi\u010dien\u0117 GE, Sonneveld E, van Haaften G, et al. ABL-class genomic breakpoint Q-PCR: a patient-specific approach for mrd monitoring in acute lymphoblastic leukemia. HemaSphere. 2023;7:e967.","journal-title":"HemaSphere"},{"key":"2958_CR44","doi-asserted-by":"crossref","unstructured":"Qian YW, Wang ES, Sait SJ, Glenn ST. Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype. Cancer Genet. 2023 278\u2013279:50\u20134.","DOI":"10.1016\/j.cancergen.2023.08.004"},{"key":"2958_CR45","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1007\/s00277-025-06481-0","volume":"104","author":"X Chen","year":"2025","unstructured":"Chen X, Ren Y, Jin Y, Li X, Ma X, Cao P, et al. First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions. Ann Hematol. 2025;104:3899\u2013902.","journal-title":"Ann Hematol"},{"key":"2958_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ng.2874","volume":"46","author":"E Papaemmanuil","year":"2014","unstructured":"Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014;46:116\u201325.","journal-title":"Nat Genet"},{"key":"2958_CR47","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1182\/blood-2010-10-314674","volume":"117","author":"FW van Delft","year":"2011","unstructured":"van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood. 2011;117:6247\u201354.","journal-title":"Blood"},{"key":"2958_CR48","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/blood-2010-03-275347","volume":"117","author":"L Kuster","year":"2011","unstructured":"Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, et al. ETV6\/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117:2658\u201367.","journal-title":"Blood"},{"key":"2958_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/sj.leu.2403182","volume":"18","author":"S H\u00fcbner","year":"2004","unstructured":"H\u00fcbner S, Cazzaniga G, Flohr T, van der Velden VHJ, Konrad M, P\u00f6tschger U, et al. High incidence and unique features of antigen receptor gene rearrangements in TEL\u2013AML1-positive leukemias. Leukemia. 2004;18:84\u201391.","journal-title":"Leukemia"},{"key":"2958_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27780","volume":"66","author":"J Hoffmann","year":"2019","unstructured":"Hoffmann J, Krumbholz M, Guti\u00e9rrez HP, Fillies M, Szymansky A, Bleckmann K, et al. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66:e27780.","journal-title":"Pediatr Blood Cancer"},{"key":"2958_CR51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41375-022-01737-4","volume":"37","author":"K Ohki","year":"2023","unstructured":"Ohki K, Butler ER, Kiyokawa N, Hirabayashi S, Bergmann AK, M\u00f6ricke A, et al. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2023;37:212\u20136.","journal-title":"Leukemia"},{"key":"2958_CR52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jmoldx.2022.04.013","volume":"24","author":"C Schwinghammer","year":"2022","unstructured":"Schwinghammer C, Koopmann J, Chitadze G, Karawajew L, Br\u00fcggemann M, Eckert C. A new view on minimal residual disease quantification in acute lymphoblastic leukemia using droplet digital PCR. J Mol Diagn JMD. 2022;24:856\u201366.","journal-title":"J Mol Diagn JMD"},{"key":"2958_CR53","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jmoldx.2022.04.014","volume":"24","author":"I Della Starza","year":"2022","unstructured":"Della Starza I, De Novi LA, Santoro A, Salemi D, Spinelli O, Tosi M, et al. Digital droplet PCR is a reliable tool to improve minimal residual disease stratification in adult philadelphia-negative acute lymphoblastic leukemia. J Mol Diagn. 2022;24:893\u2013900.","journal-title":"J Mol Diagn"},{"key":"2958_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2012.073965","volume":"98","author":"A Caye","year":"2013","unstructured":"Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98:597\u2013601.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02958-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:02:47Z","timestamp":1793649767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02958-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02958-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the article, it was noted that Supplementary Table 4 inadvertently included an extraneous internal identifier column. Supplementary Table 4 has now been replaced with an updated version removing this column. All underlying scientific data, analyses, and conclusions of the study remain unchanged.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}